Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NEMA Research, Inc.
Age
0–0
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female neonates with a gestational age of ≥ 34 - ≤44 weeks admitted into the NICU with a high probability of developing seizures (e.g., HIE, stroke, intracerebral hemorrhage, central nervous system infection)
Parental informed consent (in-person or remote consent)
Undergoing continuous video electroencephalogram (cvEEG) monitoring
Has evidence of electrographic seizure burden of at least 30 seconds/h
You may not be if
Received anticonvulsant treatment, including phenobarbital, prior to randomization (with exception of lorazepam administered for sedation \> 24 hours before enrollment)
Strong suspicion or confirmed diagnosis of brain malformation, inborn error of metabolism genetic syndrome, or major congenial malformation prior to randomization
Seizures responding to correction of hypoglycemia, hypocalcemia or any other metabolic disorder
Death appears to be imminent as assessed by the NICU attending physician
Is currently enrolled in another study assessing the same and/or similar primary/secondary endpoints with/without drug treatment.
